Feb 09, 2023 / NTS GMT
Presentation (Pre-Recorded)
Feb 09, 2023 / NTS GMT
=====================
Corporate Participants
=====================
* Pascal Soriot
AstraZeneca PLC - CEO & Executive Director
=====================
Pascal Soriot - AstraZeneca PLC - CEO & Executive Director
2022 was a year of continued strong company performance and execution of our long-term growth strategy. Our pioneering science was evident across all therapy areas, and I'm really proud of what we were able to achieve for patients around the world.
In 2023, we expect to see another year of double-digit revenue growth, excluding our COVID-19 medicines as we bring more medicines to more patients than ever before. And we plan to initiate more than 30 Phase III trials this year, 10 of which have blockbuster potential. And with our continued progress, we are on track to deliver industry-leading growth for 2025 and beyond and deliver at least 15 new medicines before the end of the decade.
My thanks to all of our team for the part they played in achieving our strong results and for
Q4 2022 AstraZeneca PLC Earnings Presentation (Pre-Recorded) Transcript
Feb 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers